leadf
logo-loader

Wall Street shares seen lower as Donald Trump set for nomination

Wall Street shares are seen opening lower midweek after a lower finish yesterday thanks to weak Chinese data and depressed oil prices.

Pictured is Donald Trump, who has  become the Republican nominee after Ted Cruz dropped out
Donald Trump has become the Republican nominee after Cruz dropped out

Wall Street shares are seen opening lower midweek after a lower finish yesterday thanks to weak Chinese data and depressed oil prices.

At the time of writing on Wednesday, European indices are also lower, with the FTSE100 down over 78 points and the German DAX down over 68 points. In France, the CAC 40 is over 28 lower.

Big news in the US is that Republican and controversial figure Donald Trump has now become the presumptive presidential nominee after Ted Cruz dropped out.

On Wall Street, the benchmark Dow Jones closed Tuesday 140 points down at 17,750, while the tech heavy Nasdaq ended over 54 down at 4,763.

The broader-based index S&P500 finished down more than 18 points to stand at 2,063.

Futures trading, meanwhile,  shows the Dow heading further lower, down 115 points; the S&P500 15.25 lower and the Nasdaq trailing over 32 points lower.

Investors will once again be kept busy by corporate earnings analysis today, with several big names expected to report.

They include,  ahead of the bell, the brewer Anheuser-Busch InBev and global oil titan  Royal Dutch Shell (NYSE: RDSA, LON:RDSB).

Time Warner (NYSE: TWX), which owns CNN, is also reporting heavily anticipated results this morning,  with shares up 0.72% in after-hours trading.

Meanwhile after the bell is closely followed electric car manufacturer Tesla (NASDAQ:TSLA) and  Marathon Oil (NYSE: MRO).

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell's Paul Anderson hails FDA approval for dental bone and tissue...

Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US....

1 day, 23 hours ago

2 min read